Three New Ideas to Protect Special Forces From the Stress of High Altitude

Mountain Sickness Clinical Trial

Official title: Three New Ideas to Protect Special Forces From the Stress of High Altitude

Status Completed

Clinical Trial Summary

Acute Mountain Sickness (AMS) is a well-documented syndrome that affects 42% of non-acclimatized individuals traveling to altitudes above 10,000 feet. Decreased barometric pressure, which leads to low blood oxygen levels, is the primary casual factor of AMS. Symptoms of AMS are characterized by headache, nausea, vomiting, dizziness, fatigue and difficultly sleeping. Moreover, when people travel to high altitude, cognitive performance and endurance exercise capacity are impaired. Therefore, the goal of this research is to identify effective pharmacological agents that will help reduce the symptoms of AMS and improve physical and cognitive performance at high altitude. The investigators will study the efficacy of the dietary supplement, quercetin, the drugs nifedipine (extended release) and methazolamide taken together, the drug metformin, and the drug nitrite in reducing symptoms of AMS and improving cognitive and exercise performance at high altitudes.

Clinical Trial Description

n/a

Related Conditions & MeSH terms

• Altitude Sickness
• Mountain Sickness

• NCT number: NCT02463357
• Study type: Interventional
• Source: University of Colorado, Denver
• Status: Completed
• Phase: Phase 4
• Start date: August 2015
• Completion date: September 2016